<DOC>
	<DOCNO>NCT00609336</DOCNO>
	<brief_summary>This phase II trial study well give combination chemotherapy together intensity-modulated radiation therapy ( IMRT ) surgery work treat patient localize pancreatic cancer remove surgery . Drugs use chemotherapy , gemcitabine hydrochloride , docetaxel , capecitabine , oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy , IMRT , delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Giving one drug ( combination chemotherapy ) together intensity-modulated radiation therapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery .</brief_summary>
	<brief_title>Combination Chemotherapy , Intensity-Modulated Radiation Therapy , Surgery Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate median overall survival patient adenocarcinoma pancreas treat induction chemotherapy , neoadjuvant chemoradiotherapy , surgical resection adjuvant chemotherapy . SECONDARY OBJECTIVES : I . To determine percent patient survive annual interval five year . II . To determine median recurrence free survival follow pancreaticoduodenectomy . III . To determine clinical response rate neoadjuvant chemotherapy chemoradiotherapy . IV . To determine pathologic response rate neoadjuvant chemotherapy chemoradiotherapy . V. To determine cancer antigen ( CA ) 19-9 tumor marker response rate neoadjuvant chemotherapy chemoradiotherapy . VI . To determine surgical completion rate complication rate follow neoadjuvant chemotherapy chemoradiotherapy . VII . To determine frequency severity toxicity associate treatment regimen . OUTLINE : INDUCTION CHEMOTHERAPY : Patients receive gemcitabine hydrochloride intravenously ( IV ) 75 minute docetaxel IV 30 60 minute day 4 11 . Patients also receive capecitabine orally ( PO ) twice daily ( BID ) day 1-14 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . NEOADJUVANT CHEMORADIOTHERAPY : Beginning 14 day completion induction chemotherapy , patient receive capecitabine PO BID day 1-14 oxaliplatin IV 2 hour day 1 8 . Patients also undergo IMRT daily day 1-5 8-13 . SURGICAL RESECTION : Approximately 2-6 week completion neoadjuvant chemoradiotherapy , patient undergo pancreaticoduodenectomy . ADJUVANT CHEMOTHERAPY : Beginning 4-10 week surgery , patient receive gemcitabine hydrochloride IV 30 minute oxaliplatin IV 2 hour day 1 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Patients receive gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients must histologically cytologically confirm diagnosis localize , resectable borderline resectable , pancreatic adenocarcinoma T1T3 , N0N1 , M0 ; stage determine helical multiphase compute tomography ( CT ) and/or endoscopic ultrasound accord publish guideline ; resectability determine treat surgeon publish guideline ( National Comprehensive Cancer Network ) Resectable Disease Head/Body/Tail pancreas : No distant metastasis Clear fat plane around celiac superior mesenteric artery ( SMA ) Patent superior mesenteric vein ( SMV ) portal vein ( PV ) Borderline Resectable Disease Head/Body pancreas : Tumor abutment SMA SMV/portal vein impingement occlusion involve short segment , open vein proximally distally ( proximal vein occlude portal vein branch disease unresectable ) Colon mesocolon invasion Gastroduodenal artery ( GDA ) encasement origin hepatic artery Tail pancreas : Adrenal , colon mesocolon , kidney invasion Preoperative evidence biopsypositive peripancreatic lymph node No prior therapy pancreatic cancer Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Leucocytes &gt; = 3,000/uL Absolute Neutrophil Count &gt; = 1,500/uL Platelets &gt; = 100,000/uL Total Bilirubin : If within normal limit ( WNL ) = &lt; 2.0 , subject eligible If &gt; 2.0 &lt; 6.0 , subject eligible IF biliary stent total bilirubin decrease If &gt; = 6.0 , subject eligible Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvic transaminase [ SGPT ] ) = &lt; 2.5 X institutional upper limit normal = &lt; 1.5 X upper limit normal ( ULN ) alkaline phosphatase ( Alk Phos ) &gt; 2.5 X ULN subject biliary stent liver function test ( LFTs ) decrease subject eligible Creatinine clearance &gt; = 30 % Negative pregnancy test woman childbearing potential ; woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability swallow retain oral medication Ability understand willingness sign write informed consent document Patients may receive investigational agent Histology adenocarcinoma Patients permanently unresectable pancreatic adenocarcinoma determine treat physician publish guideline ( National Comprehensive Cancer Network ) Unresectable disease Head pancreas : Distant metastasis ( include celiac and/or paraaortic ) SMA , celiac encasement SMV/portal occlusion Aortic , inferior vena cava ( IVC ) invasion encasement Invasion SMV transverse mesocolon Body pancreas : Distant metastasis ( include celiac and/or paraaortic ) ; discretion treat surgeon , body tail lesion positive celiac and/or paraaortic node close vicinity primary may borderline rather unresectable SMA , celiac , hepatic encasement SMV/portal extend occlusion Aortic invasion Tail pancreas : Distant metastasis ( include celiac and/or paraaortic ) SMA , celiac encasement Rib , vertebral invasion History allergic reaction attribute compound similar chemical biologic composition gemcitabine , docetaxel , capecitabine , oxaliplatin agent use study Patients receive prior chemotherapy radiotherapy diagnosis pancreatic cancer Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Inability comply study and/or followup procedure Pregnancy lactation Human immunodeficiency virus ( HIV ) positive patient receive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>